Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price objective lowered by Barclays from $11.00 to $9.00 in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. SGMO has been the subject of a number of other reports. Stifel Nicolaus lowered […]
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its target price cut by Wells Fargo & Company from $5.00 to $4.00 in a research note published on Thursday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on SGMO. Barclays cut […]
Wells Fargo & Company Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $4 00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Cut to $9 00 by Analysts at Barclays modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The CAR T-cell therapy market is expected to grow by USD 1,999 million from 2022 to 2027, progressing at a CAGR of 13.44% as per the latest.